Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-08-13), AFT Pharmaceuticals's 10-Year Sharpe Ratio is 0.16.
AFT Pharmaceuticals (ASX:AFP) 10-Year Sharpe Ratio Explanation
The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
AFT Pharmaceuticals 10-Year Sharpe Ratio Related Terms
ASX:AFP vs ZTS, UTHR, VTRS: 10-Year Sharpe Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals 10-Year Sharpe Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's 10-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's 10-Year Sharpe Ratio falls into.
AFT Pharmaceuticals 10-Year Sharpe Ratio Calculation
The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.
AFT Pharmaceuticals (ASX:AFP) has a 10-Year Sharpe Ratio of 0.16 as of Aug. 13, 2026. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' 10-Year Sharpe Ratio too high?
AFT Pharmaceuticals' current 10-Year Sharpe Ratio is 0.16. Overall, AFT Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' 10-Year Sharpe Ratio compare to ZTS and UTHR?
AFT Pharmaceuticals' 10-Year Sharpe Ratio of 0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Sharpe Ratio for a Drug Manufacturers company?
A good 10-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 10-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Sharpe Ratio mean?
A high 10-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current 10-Year Sharpe Ratio is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Modestly Overvalued. The stock's GF Value™ is A$3.45, compared to a current price of A$3.87 — trading 12.2% above its estimated fair value. The current 10-Year Sharpe Ratio is 0.16. AFT Pharmaceuticals' overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Sharpe Ratio calculated?
10-Year Sharpe Ratio is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current 10-Year Sharpe Ratio is 0.16 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued.
The current stock price of A$3.87 is trading 12.2% above its estimated GF Value™ of A$3.45.
GuruFocus considers AFT Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:AFP:
10-Year Sharpe Ratio: 0.16
GF Value™: A$3.45 vs. price of A$3.87 (12.2% above fair value)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
87GF Score
Get the complete analysis for ASX:AFP
10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
